AGP Executive Report
Last update: 7 hours agoBlockchain: Zilliqa plans to replace its standalone network with an Ethereum-secured platform for regulated institutions. Liechtenstein’s LTIN will run the sequencer and issue verified institutional identities. Existing token holders need no immediate action. Biotech: Anktiva has reached its first patients in Europe, treated in Germany and Austria. The bladder cancer therapy’s conditional EU approval also covers Liechtenstein. Pharmaceuticals: Strong European sales of Basilea’s antifungal Cresemba triggered a $37.5 million milestone payment; the drug is approved in Liechtenstein and other European markets.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.